COVID-19 Research Paper Volume 13, Issue 5 pp 6236—6246

Elevated frequencies of CD14+HLA-DRlo/neg MDSCs in COVID-19 patients

Increased %CD14+HLA-DRlo/neg MDSCs in COVID-19 patients. (A) Representative gating strategy used to identify CD14+HLA-DRlo/neg MDSCs in whole blood. (B) Flow cytometry overlay histograms for HLA-DR expressions on monocytes in HC, non-ICU COVID-19 patient and ICU COVID-19 patient. (C) Comparisons of CD14+HLA-DRlo/neg MDSC(%) in HCs group, non-ICU group and ICU group. Abbreviations: ICU, intensive care unit; HCs, healthy controls; MDSC, myeloid-derived suppressor cells.

Figure 1. Increased %CD14+HLA-DRlo/neg MDSCs in COVID-19 patients. (A) Representative gating strategy used to identify CD14+HLA-DRlo/neg MDSCs in whole blood. (B) Flow cytometry overlay histograms for HLA-DR expressions on monocytes in HC, non-ICU COVID-19 patient and ICU COVID-19 patient. (C) Comparisons of CD14+HLA-DRlo/neg MDSC(%) in HCs group, non-ICU group and ICU group. Abbreviations: ICU, intensive care unit; HCs, healthy controls; MDSC, myeloid-derived suppressor cells.